glp 1 oral drugs New GLP-1 Outperforms Semaglutide What to Make of the
Description
Rizvi, A., Rizzo, M
In 2018, the average cost for Segal clients was $0.50 per-member, per-month (PMPM)
This analysis examines CMSs Medicare Part D claims data from 2019 to 2024 to document the increase in the number of beneficiaries being treated with GLP-1 drugs and the growth in Medicare spending and claims for GLP-1s
In the SURPASS-2 trial, tirzepatide did not cause relevant changes in mean calcitonin levels
however, its effects last for only a few hours
Wilbon, S
